MacroGenics Provides Vobramitamab Duocarmazine Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
BTIG Downgrades MacroGenics (MGNX) to Neutral
July 31, 2024 4:18 PM EDTBTIG analyst Kaveri Pohlman downgraded MacroGenics (NASDAQ: MGNX) from Buy to Neutral.
The analyst comments "MacroGenics has discontinued the Tamarack study, evaluating vobra duo for mCRPC, after a review of its risk/benefit profile. This decision follows the study's IDMC recommendation to discontinue treatment for the remaining study participants who were eligible to receive additional doses. For reference, the majority... More
